# Contents

**World Journal of Hepatology**

## REVIEW

883  Malnutrition in cirrhosis: More food for thought  
*Chapman B, Sinclair M, Gow PJ, Testro AG*

## MINIREVIEWS

897  Paraneoplastic syndromes in cholangiocarcinoma  
*Rahman SU, Sana MK, Tahir Z, Ali A, Shah PA*

908  Noninvasive scores for the prediction of esophageal varices and risk stratification in patients with cirrhosis  
*Bangaru S, Benhammou JN, Tabibian JH*

919  Natremia and liver transplantation: The right amount of salt for a good recipe  
*Lenci I, Milana M, Grassi G, Signorello A, Aglitti A, Baiocchi L*

## ORIGINAL ARTICLE

### Basic Study

931  Inhibition of vascular adhesion protein-1 modifies hepatic steatosis *in vitro* and *in vivo*  
*Shepherd EL, Karim S, Newsome PN, Lalor PF*

949  Aceclofenac-induced hepatotoxicity: An ameliorative effect of *Terminalia belirrica* fruit and ellagic acid  
*Gupta A, Pandey A*

965  Obeticholic acid attenuates human immunodeficiency virus/alcohol metabolism-induced pro-fibrotic activation in liver cells  
*New-Aaron M, Ganesan M, Dagar RS, Kharbanda KK, Poluektova LY, Osna NA*

976  Screening and identification of bioactive compounds from citrus against non-structural protein 3 protease of hepatitis C virus genotype 3a by fluorescence resonance energy transfer assay and mass spectrometry  
*Khan M, Rauf W, Habib F, Rahman M, Iqbal M*

### Retrospective Cohort Study

993  Cannabis use history is associated with increased prevalence of ascites among patients with nonalcoholic fatty liver disease: A nationwide analysis  
*Choi CJ, Weiss SH, Nasir UM, Pyrsopoulos NT*

1004  Phase angle and non-alcoholic fatty liver disease before and after bariatric surgery  
*Teixeira J, Marroni CA, Zubiaurre PR, Henz A, Faina L, Pinheiro GK, Mottin CC, Fernandes SA*
# Contents

**World Journal of Hepatology**  
Monthly Volume 12 Number 11 November 27, 2020

## Retrospective Study

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1020</td>
<td>Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma</td>
<td>Sempokuya T, Wien EA, Pattison RJ, Ma J, Wong LL</td>
</tr>
<tr>
<td>1031</td>
<td>Circulating miR-21-5p level has limited prognostic value in patients with hepatocellular carcinoma and is influenced by renal function</td>
<td>Franck M, Thon C, Schütte K, Malfertheiner P, Link A</td>
</tr>
<tr>
<td>1046</td>
<td>Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases</td>
<td>Tarao K, Nozaki A, Komatsu H, Komatsu T, Taguri M, Tanaka K, Chuma M, Numata K, Maeda S</td>
</tr>
<tr>
<td>1055</td>
<td>Non-invasive splenic parameters of portal hypertension: Assessment and utility</td>
<td>Ahmad AK, Atzori S, Maurice J, Taylor-Robinson SD, Lim AK</td>
</tr>
<tr>
<td>1067</td>
<td>Outcome of gastric antral vascular ectasia and related anemia after orthotopic liver transplantation</td>
<td>Emhmed Ali S, Benrajab KM, Dela Cruz AC</td>
</tr>
</tbody>
</table>

## Clinical Trials Study

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

## Observational Study

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

## Randomized Controlled Trial

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

## SYSTEMATIC REVIEWS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1115</td>
<td>Clinical utility of viscoelastic testing in chronic liver disease: A systematic review</td>
<td>Wei H, Child LJ</td>
</tr>
</tbody>
</table>

## CASE REPORT

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1128</td>
<td>Hepatocellular carcinoma with tumor thrombus extends to the right atrium and portal vein: A case report</td>
<td>Gomez-Puerto D, Mirallas O, Vidal-González J, Vargas V</td>
</tr>
</tbody>
</table>
ABOUT COVER

Associate editor of World Journal of Hepatology, Dr. Yong-Ping Yang is a Distinguished Professor at Peking University Health Science Center in Beijing, China. Having received his Bachelor’s degree from Yanbian University in 1985, Dr. Yang undertook his postgraduate training at PLA Medical College, receiving his Master’s degree in 1992. He rose to Chief Physician in the Hepatology Division of the Fifth Medical Center of the Chinese PLA General Hospital in 2003 and has held the position since. His ongoing research interests involve liver fibrosis, cirrhosis and hepatocellular carcinoma, with a particular focus on cryoablation and cryo-immunotherapy for hepatocellular carcinoma. Currently, he serves as Chairman of the Department of Liver Disease of the Chinese PLA General Hospital and as President of the Chinese Research Hospital Association for the Study of the Liver Disease. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of World Journal of Hepatology (WJH, World J Hepatol) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The WJH is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Li-Li Wang; Production Department Director: Yan-Xiaojian Wu; Editorial Office Director: Jia-Ping Yan.
Retrospective Study

Outcome of gastric antral vascular ectasia and related anemia after orthotopic liver transplantation

Saad Emhmed Ali, Karim M Benrajab, Anna Christina Dela Cruz

ORCID number: Saad Emhmed Ali 0000-0002-3481-0365; Karim M Benrajab 0000-0002-7988-1159; Anna Christina Dela Cruz 0000-0002-1083-096X.

Author contributions: Emhmed Ali S and Dela Cruz AC provided the conception and designed the study; Emhmed Ali S, Benrajab K and Dela Cruz AC analyzed and interpreted the data and wrote the manuscript; all authors have read and approved the final manuscript.

Institutional review board statement: The study was reviewed and approved by the University of Kentucky Institutional Review Board (Approval No 54669).

Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

Conflict-of-interest statement: Authors have no relevant relationships or conflict of interest to disclose.

Data sharing statement: No additional data are available.

Open-Access: This article is an Open-Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International (CC BY-NC-ND) license. Please see License and Permissions for more information. DOI: 10.4254/wjh.v12.i11.1067

Abstract

BACKGROUND
Gastric antral vascular ectasia (GAVE) is a significant complication of cirrhosis. Numerous medical, surgical, and endoscopic treatment modalities have been proposed with varied satisfactory results. In a few small studies, GAVE and associated anemia have resolved after orthotopic liver transplantation (OLT).

AIM
To assess the impact of OLT on the resolution of GAVE and related anemia.

METHODS
We retrospectively reviewed clinical records of adult patients with GAVE who underwent OLT between September 2012 and September 2019. Demographics and other relevant clinical findings were collected, including hemoglobin levels and upper endoscopy findings before and after OLT. The primary outcome was the resolution of GAVE and its related anemia after OLT.

RESULTS
Sixteen patients were identified. Mean pre-OLT Hgb was 7.7 g/dL and mean 12 mo post-OLT Hgb was 11.9 g/dL, (P = 0.001). Anemia improved (defined as Hgb increased by 2g) in 87.5% of patients within 6 to 12 mo after OLT and resolved completely in half of the patients. Post-OLT esophagogastroduodenoscopy was performed in 10 patients, and GAVE was found to have resolved entirely in 6 of those patients (60%).

CONCLUSION

Saad Emhmed Ali, Karim M Benrajab, Anna Christina Dela Cruz

Saad Emhmed Ali, Division of Hospital Medicine, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY 40536, United States

Karim M Benrajab, Anna Christina Dela Cruz, Division of Digestive Diseases and Nutrition, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY 40536, United States

Corresponding author: Karim M Benrajab, MD, Assistant Professor, Division of Digestive Diseases and Nutrition, Department of Internal Medicine, University of Kentucky College of Medicine, 800 Rose Street, MN649, Lexington, KY 40536, United States. karimbenrajab@gmail.com
Although GAVE and associated anemia completely resolved in the majority of our patients after OLT, GAVE persisted in a few patients after transplant. Further studies in a large group of patients are necessary to understand the causality of disease and to better understand the factors associated with the persistence of GAVE post-transplant.

Key Words: Liver cirrhosis; Iron deficiency anemia; End-stage liver disease; Gastroscopy; Gastrointestinal hemorrhage; Liver transplantation

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Citation: Emhmed Ali S, Benrajab KM, Dela Cruz AC. Outcome of gastric antral vascular ectasia and related anemia after orthotopic liver transplantation. World J Hepatol 2020; 12(11): 1067-1075

Core Tip: In this retrospective study, cirrhotic patients who had gastric antral vascular ectasia (GAVE) with anemia and underwent orthotopic liver transplant (OLT) between September 2012 and September 2019 were reviewed to evaluate the impact of OLT on resolution of GAVE and associated anemia. A total of 296 patients underwent OLT during the study period; sixteen patients had GAVE. Anemia improved in the majority of patients in 6 to 12 mo post-OLT, and of the 10 patients who had a post-OLT esophagogastroduodenoscopy, GAVE was found to have completely resolved in 6 of those patients. We concluded that GAVE and associated anemia completely resolved in the majority of our patients post-OLT.

INTRODUCTION

Gastric antral vascular ectasia (GAVE) is frequently found in patients with cirrhosis. The estimated prevalence in cirrhotic patients with upper gastrointestinal (GI) bleeding is around 6%, and in cirrhotic patients without apparent upper GI bleeding is about 12%. Another study found that GAVE was present in 1 in 40 of cirrhotic patients who underwent screening esophagogastroduodenoscopy (EGD) during liver transplant evaluation. The clinical presentation extends from occult hemorrhage to transfusion-dependent chronic iron deficiency anemia.

Diagnosed endoscopically, GAVE lesions are located primarily in the antrum of the stomach, and appear as red spots that are either organized in stripes that project radially from the pylorus (“watermelon stomach”) or organized in a diffuse punctate (“honeycomb”) pattern. The exact etiology of GAVE remains unclear, although several hypotheses have been proposed, including mechanical stress, hemodynamic alterations, and humoral and autoimmune factors. Numerous medical, surgical, and endoscopic treatment modalities such as endoscopic band ligation, endoscopic thermal therapy with argon plasma coagulation (APC), and radiofrequency ablation have been proposed with varying satisfactory results. In a few small studies, GAVE and associated anemia have resolved after orthotopic liver transplantation (OLT).

The aim of this study was to further investigate the influence of OLT on the resolution of GAVE and associated anemia.

MATERIALS AND METHODS

A retrospective chart review was conducted of all adult patients with diagnosis of cirrhosis and GAVE who underwent OLT at the University of Kentucky Medical Center (UKMC) between September 2012 and September 2019. Patient demographics, body mass index (BMI), comorbidities, Model of End-stage Liver Disease-sodium (MELD-Na) score at the time of GAVE diagnosis, etiology of cirrhosis, use of proton...
pump inhibitors (PPI); GAVE presentation; type of endoscopic treatment utilized; lowest hemoglobin (Hgb) pre-OLT; hemoglobin at 3 mo, 6 mo, 9 mo, and 12 mo post-OLT; and post-OLT EGD findings were collected.

All the data mentioned above were collected from the patient’s electronic medical records and stored in a password-protected excel sheet for analysis. The diagnosis of GAVE was obtained from the endoscopy reports. A single endoscopist/hepatologist independently reviewed all endoscopic images to confirm report findings. The primary outcome was the resolution of GAVE and associated anemia post-OLT.

This study was approved by the UKMC Institutional Review Board. No organs from executed prisoners were used.

RESULTS

Of 296 patients who underwent OLT during the study period, 16 (5.4%) had diagnosis of GAVE.

The individual patient cases are summarized in Table 1. All Caucasians, with the majority being female (62.5%) with a mean age of 56.5 years and mean BMI of 31.6. The average MELD-Na score at the time of GAVE diagnosis was 20.4. The most common etiology of cirrhosis was Non-alcoholic steatohepatitis (NASH, 44%).

Twelve patients (75%) had concomitant portal hypertensive gastropathy, and 13 (81%) had chronic kidney disease (defined as a GFR < 60 mL/min/1.73 m² for > 3 mo).

Thirteen patients (81%) were on a PPI. All patients presented with anemia, with 50% having at least one episode of overt bleeding requiring a blood transfusion prior to transplant. Five of those without overt bleed had iron deficiency anemia. Half of the patients were treated endoscopically, with APC being the most common treatment (31%), and 25 % of patients underwent banding.

The pattern of GAVE varied in our patient cohort: Six patients had diffuse punctate GAVE (Figure 1), five patients had linear/striped pattern (Figure 2), two had patchy mild punctate GAVE, two patients had nodular polypoid GAVE characterized by polypoid lesions with exudate (Figure 3), and one had nodular striped GAVE (Figure 4). The patterns evolved in two patients, with the initial EGD showing a linear pattern and subsequent EGD showing a nodular/polypoid GAVE.

Mean pre-OLT Hgb was 7.7 g/dL compared to 11.9 g/dL at 12 mo post-OLT (P = 0.001). Anemia improved in 87.5 % (defined as Hgb increase by 2g) of patients (n = 14) & resolved entirely in 50 % of patients within 6 to 12 mo after OLT.

Only two patients required blood transfusion after three months post-transplant. One patient was five months, and the other patient was three years post-OLT; however, neither had evidence of bleeding.

Post-OLT EGD was performed in 10 patients. The mean time between OLT and post-OLT EGD was 27.9 mo. Among the 10 patients who underwent post-OLT EGD, GAVE was found to have resolved entirely in six patients (60%).

It is unclear why GAVE persisted in four out of ten patients who underwent post-OLT EGD. The first patient had psoriatic arthropathy. The second patient had GAVE sixteen years after transplant and had underlying polycythemia vera and chronic splenic thrombosis post-transplant with varices. The third patient had recurrent biopsy-proven cirrhosis. The fourth patient had persistent nodular GAVE, which required two endoscopic band ligations at two and ten weeks post-OLT with an endoscopic resolution of GAVE and associated anemia at six months post-OLT. The pattern of post-transplant GAVE varied in these four patients. Two patients had polypoid GAVE, one patient had linear GAVE, which later evolved into polypoid GAVE, and one patient had patchy mild punctate GAVE.

DISCUSSION

Gastric antral vascular ectasia is a common finding in patients with cirrhosis and often presents as chronic anemia. The endoscopic pathognomonic feature of GAVE is columns of red tortuous ectatic vessels along the folds of the antrum[20]. Histologically, GAVE is characterized by mucosal vascular ectasia, spindle cell proliferation, fibrohyalinosis, and fibrin thrombi[21]. It is a disease with focal distribution[22]. Therefore, a negative biopsy does not rule out GAVE[23].

Although GAVE has been historically described as a “watermelon stomach,” the diffuse pattern of GAVE endoscopically was found to be more frequent in cirrhotic patients in one study[18]. In contrast, the classic watermelon form was found to be more
### Table 1 Clinical characteristics of patients with gastric antral vascular ectasia who underwent orthotopic liver transplantation

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (yr)</th>
<th>Gender</th>
<th>BMI</th>
<th>Etiology of liver disease</th>
<th>MELD-Na score at GAVE diagnosis</th>
<th>Pre-OLT Hgb (g/dL)</th>
<th>GAVE pattern</th>
<th>Endoscopic therapy</th>
<th>Resolution of GAVE post-OLT</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>66</td>
<td>F</td>
<td>33.7</td>
<td>NASH</td>
<td>26</td>
<td>8</td>
<td>Diffuse punctate GAVE</td>
<td>APC</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>55</td>
<td>F</td>
<td>28</td>
<td>cryptogenic</td>
<td>15</td>
<td>8.7</td>
<td>Pre-OLT: Striped GAVE</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>50</td>
<td>M</td>
<td>42.7</td>
<td>NASH</td>
<td>32</td>
<td>7</td>
<td>Linear/striped GAVE</td>
<td>APC</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>57</td>
<td>F</td>
<td>32.9</td>
<td>cryptogenic</td>
<td>13</td>
<td>7.2</td>
<td>Striped and nodular GAVE</td>
<td>Banding</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>59</td>
<td>F</td>
<td>35.7</td>
<td>NASH</td>
<td>14</td>
<td>6.7</td>
<td>Pre and post-OLT: Nodular polypoid GAVE with exudate</td>
<td>Banding</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>51</td>
<td>M</td>
<td>23</td>
<td>Alcohol</td>
<td>30</td>
<td>7.1</td>
<td>Diffuse punctate GAVE</td>
<td>APC</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>51</td>
<td>M</td>
<td>27</td>
<td>NASH</td>
<td>23</td>
<td>7.2</td>
<td>Diffuse punctate GAVE</td>
<td>APC</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>57</td>
<td>F</td>
<td>22</td>
<td>Alcohol</td>
<td>23</td>
<td>7.5</td>
<td>Diffuse punctate GAVE</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>59</td>
<td>F</td>
<td>32.6</td>
<td>NASH</td>
<td>31</td>
<td>7.7</td>
<td>Diffuse punctate GAVE</td>
<td>Banding</td>
<td>Yes</td>
</tr>
<tr>
<td>10</td>
<td>40</td>
<td>M</td>
<td>36.6</td>
<td>Alcohol, HCV</td>
<td>Post-OLT diagnosis</td>
<td>6.9</td>
<td>Post-OLT: Linear/striped GAVE</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>11</td>
<td>55</td>
<td>M</td>
<td>30.8</td>
<td>PSC</td>
<td>13</td>
<td>8.8</td>
<td>Nodular polypoid GAVE with exudate</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>12</td>
<td>58</td>
<td>M</td>
<td>17.8</td>
<td>Alcohol</td>
<td>12</td>
<td>7.3</td>
<td>Diffuse punctate GAVE</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>13</td>
<td>62</td>
<td>F</td>
<td>47.6</td>
<td>HCV</td>
<td>30</td>
<td>7.6</td>
<td>Linear/striped GAVE</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>14</td>
<td>57</td>
<td>F</td>
<td>25.5</td>
<td>Budd Chiari syndrome</td>
<td>Post-OLT diagnosis</td>
<td></td>
<td>Post-OLT: Patchy mild punctate GAVE</td>
<td>None</td>
<td>No</td>
</tr>
<tr>
<td>15</td>
<td>67</td>
<td>F</td>
<td>35.5</td>
<td>NASH</td>
<td>15</td>
<td>9.6</td>
<td>Patchy mild punctate GAVE</td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td>16</td>
<td>60</td>
<td>F</td>
<td>32.5</td>
<td>NASH</td>
<td>8</td>
<td>7.5</td>
<td>Linear/striped GAVE</td>
<td>APC</td>
<td>Yes</td>
</tr>
</tbody>
</table>

APC: Argon Plasma Coagulation; BMI: Body mass index; F: Female; GAVE: Gastric antral vascular ectasia; HCV: Hepatitis C virus; Hgb: Hemoglobin; M: Male; MELD-Na: Model for End-Stage Liver Disease- Sodium level; NASH: Non-alcoholic Steatohepatitis; OLT: Orthotopic liver transplantation; PSC: Primary sclerosing cholangitis.

Figure 1 Endoscopic image showing a diffuse punctate pattern of gastric antral vascular ectasia.

common in non-cirrhotic patients[21]. In our cohort, 50% of patients were found to have diffuse punctate GAVE, 31% had a linear/striped pattern, and 19% with nodular type. The gender distribution in our study seems to be similar to other studies. In our study, the cirrhotic GAVE patients were predominately female (62.5%) with a mean age of 56.2 years. Other studies have shown a female predominance (71%) of GAVE in cirrhotic patients with a mean age of 73 years, and a male predominance (75%) in non-
Emhmed Ali S et al: Impact of OLT on GAVE

Figure 2  Endoscopic image showing a linear and striped pattern of gastric antral vascular ectasia.

Figure 3  Endoscopic image showing a nodular polypoid pattern of gastric antral vascular ectasia.

Figure 4  Endoscopic image showing a nodular and striped pattern of gastric antral vascular ectasia.

cirrhotic GAVE patients, with a mean age of 65 years

The exact pathophysiological mechanism that leads to GAVE remains unclear. It is highly essential to differentiate GAVE from portal hypertensive gastropathy (PHG) because they are treated differently. PHG mainly causes mucosal changes in the fundus and corpus\(^1\), whereas GAVE is limited to antrum\(^1\). It is possible that portal hypertension has no significant role in the development of GAVE for several reasons, such as absence of correlation between the severity of portal hypertension and degree of vascular ectasia\(^1\), and non-resolution of GAVE after reduction in portal pressure\(^2\). Quintero \(et \: al\)^3 linked low levels of pepsinogen, high levels of gastrin, and achlorhydria, with GAVE, and other studies have reported improvement in GAVE and reduction in gastrin levels after cessation of proton pump inhibitor\(^4\). In our study, 13 patients (81\%) were taking proton pump inhibitors before and after OLT. Prostaglandin E2 has a gastric vasodilator effect and has been considered to play a role in the development of GAVE\(^1\). Another study by Lowes \(et \: al\)^3 found a proliferation of

cirrhotic GAVE patients, with a mean age of 65 years\(^1\).
Emhmed Ali S et al. Impact of OLT on GAVE

GAVE is a significant cause of morbidity and mortality in patients with cirrhosis. Although GAVE and associated anemia completely resolved in the majority of our patients after liver transplantation, GAVE persisted in a few patients post-OLT. Large, neuroendocrine cells that secrete 5-hydroxytryptamine and vasoactive peptide close to the ectatic blood vessels. Mechanical stress theory has been suggested by Charneua et al[1] to be playing a role in cirrhotic GAVE patients after they found abnormal motility patterns on antral motility studies. In non-cirrhotic GAVE patients, many other medical conditions have been described, such as autoimmune disease, acute myeloid leukemia, hypertension, chronic renal failure, ischemic heart disease, bone marrow transplantation, scleroderma, and familial Mediterranean fever[12-19]. The most frequent associated autoimmune conditions are connective tissue diseases followed by Raynaud’s phenomenon and sclerodactyly[20].

Bleeding GAVE can be very problematic and challenging to manage. Several endoscopic interventions and medications are available[21,22]. In three previous small studies, GAVE and associated anemia resolved after liver transplantation[16,17]. Reduction in portal hypertension via medical use of beta-blockers or transjugular intrahepatic portosystemic shunt (TIPS) placement has failed to accomplish resolution of GAVE or associated anemia in cirrhotic patients with portal hypertension[23,24]. None of our patients had TIPS before the diagnosis of GAVE. One patient had TIPS a month just before the transplant, and TIPS was done eighteen months after diagnosis of GAVE for refractory ascites. Before the transplant, eight of our patients underwent endoscopic treatment with APC as the most commonly used method. None of our patients received medical treatment, such as Tranexamic acid.

Our study further supports that GAVE in cirrhotic patients may resolve after OLT. Six out of ten patients who underwent post-OLT EGD have complete resolution of GAVE. The potential explanations for persistent GAVE among the other four patients include an underlying rheumatologic condition, which can also cause non-cirrhotic GAVE in the first patient, underlying chronic splenic vein thrombosis in the second patient, recurrent cirrhosis in the third patient, and delayed resolution of GAVE after transplant since GAVE was seen fairly recently post-transplant, noted at two and ten weeks post-transplant with the resolution of anemia in the fourth patient.

The associated anemia entirely resolved in half of our patients and improved in 87.5% of patients six to twelve months after OLT. Anemia is common in cirrhotic patients; however, it is usually complex, and may be influenced by several factors, including etiology of cirrhosis and degree of portal hypertension[25,26]. Portal hypertension and hypersplenism can be contributing factors to anemia in cirrhosis; however, the magnitude of the effect is unclear[27,28]. Furthermore, Vincent et al[17] reported resolution of GAVE and anemia in 2 patients post OLT even with persistent evidence of portal hypertension.

One would speculate that the associated resolution of liver dysfunction would lead to the resolution of GAVE after transplant. GAVE was frequently found in patients with more advanced liver disease and has been reported to resolve after liver transplantation[23,27]. In our cohort at the time of GAVE diagnosis, the mean MELD-NA score was 20.4.

The limitations of the current study include retrospective design with a small sample size. EGDs were also performed by several different endoscopists performed EGDs; however, we attempted to control for this by having one endoscopist/hepatologist review all endoscopic images. Also, only 10 patients had undergone EGD post-OLT. The patients were not treated with the same endoscopic modality, and there was no established endoscopic protocol to eradicate GAVE. Indeed, there is usually no standard treatment modality since the type of endoscopic treatment will depend on the pattern of GAVE and previous endoscopic therapies, with the preferable use of banding for most patients with nodular GAVE and APC in all other patterns of GAVE (linear and punctate GAVE). Not all patients in our cohort had histologic confirmation of GAVE, and this could raise the possibility of overlap between GAVE and PHG. Despite these limitations, this study offers the largest number of patients with GAVE who underwent liver transplantation, and our findings corroborate those from previous studies showing that GAVE and associated anemia resolve in the majority of patients who underwent liver transplantation. It also further explored the possible underlying mechanisms for persistent GAVE after OLT in four out of ten patients who had post-OLT EGD.

CONCLUSION

GAVE is a significant cause of morbidity and mortality in patients with cirrhosis. Although GAVE and associated anemia completely resolved in the majority of our patients after liver transplantation, GAVE persisted in a few patients post-OLT. Large,
prospective studies using consistent diagnostic criteria for GAVE and planned follow-up EGDs after OLT are needed to better understand the factors may contribute to persistence of GAVE post-transplant.

ARTICLE HIGHLIGHTS

Research background
Gastric antral vascular ectasia (GAVE) is a well-recognized cause of gastrointestinal bleeding in cirrhotic patients. The etiology of GAVE remains unclear, although several humoral, autoimmune, mechanical stress, and pharmacological (proton pump inhibitor use) hypotheses have been described. Different treatment modalities have been proposed with varying results. Orthotopic liver transplantation (OLT), which is often recommended for patients with significant complications due to end-stage liver disease, has also been shown to be beneficial treatment for resolution of GAVE and associated anemia in a few small studies.

Research motivation
To evaluate the relation between GAVE and associated anemia and OLT.

Research objectives
To assess the impact of OLT on resolution of the natural course of GAVE and associated anemia.

Research methods
A retrospective chart review was conducted of adult patient with GAVE who underwent liver transplant between September 2012 and September 2019. Demographics and other relevant findings, including hemoglobin levels, Model of End-stage Liver Disease-sodium score, GAVE presentation, and upper endoscopy findings before and after OLT were collected.

Research results
Sixteen patients were identified, all Caucasians and predominantly female (62.5%) with a mean age of 56.5 years. The most common etiology for cirrhosis was NASH (44%). All patients presented with anemia, with 50% presenting with overt bleed and required transfusions prior to transplant. Mean pre-OLT Hgb was 7.7, and the mean 12 mo post-OLT Hgb was 11.9 ($P = 0.001$). Anemia improved in 87.5% of patients ($n = 14$) within 6 to 12 mo after OLT and resolved completely in half of the patients. Post-OLT esophagogastroduodenoscopy was performed in 10 patients, and GAVE resolved entirely in 6 of those patients (60%).

Research conclusions
Although GAVE and associated anemia completely resolved in the majority of our patients after liver transplantation, GAVE persisted in a few patients after transplant.

Research perspectives
Large prospective studies are needed to better understand what factors may contribute to persistent GAVE post-liver transplant.

REFERENCES

Emhmed Ali S et al. Impact of OLT on GAVE

Quintero E, Pique JM, Bomba JA, Bords JM, Sentis J, Elena M, Bosch J, Rodes J. Gastric mucosal vascular ectasias causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. Gastroenterology 1987; 93: 1054-1061 [PMID: 3496659 DOI: 10.1016/0016-5085(87)90509-5]


Spahr LI, Villeneuve JP, Dufresne MP, Tassé D, Bui B, Willems B, Fenyves D, Ponier-Layrargues G. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut 1999; 44: 739-749 [PMID: 10205216 DOI: 10.1136/gut.44.5.739]


